velpatasvir or daclatasvir (pangenotypic)

This topic has 3 replies, 4 voices, and was last updated 9 years, 4 months ago by sonix.

Viewing 3 posts - 1 through 3 (of 3 total)

Author

Posts
21 December 2015 at 10:39 am #6886
Jimmy6429
- Topics: 0
- Replies: 52
- Total: 52
- Recovery Champion
@jimmy6429
Yes the sof/dac looks pretty good by the numbers, sadly compassion and science take a back seat to profit and politics.
Jim

3 years cured, Sof/Dac, thanks Doc Freeman, hepc only a distant memory, go for it ppl
21 December 2015 at 12:02 pm #6893
Dr James
- Topics: 264
- Replies: 1,968
- Total: 2,232
- Guardian Angel
@fixhepc
http://www.gilead.com/news/press-releases/2015/9/gilead-announces-svr12-rates-from-four-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-sof-and-velpatasvir-vel-gs5816-for-the-treatment-of-all-six-hepatitis-c-genotypes

Treatment emergent serious adverse events occurred in 18 percent of patients and nine patients died.

If you remove the placebo patients the n was 1593 so the death rate was 1 in 177.

YMMV
21 December 2015 at 4:28 pm #6946
sonix
- Topics: 7
- Replies: 158
- Total: 165
- Guardian Angel
@sonix
The overall cure rate in ASTRAL-1 of 99% looks good but I’d imagine comparable tests of sof/dac and sof/led would be in the same ballpark.

The majority of serious adverse events and deaths were associated with advanced liver disease.

Surely some patients with advanced liver disease would die in 12/24 weeks whether treated or not.

M 61yo HCV+ ~ 30 yrs Gt1a F2 VL 223,000 ALT 54 AST 42 Tx start Sof/Dac 17Dec15.
SVR4 at 7Apr16 ALT 22 AST 22
SVR12 at 9Jun16 ALT 23 AST 25
Melbourne, Australia
Author

Posts

Viewing 3 posts - 1 through 3 (of 3 total)

You must be logged in to reply to this topic.